ALK-Abelló | Evaluate

November 27, 2019

Investors see no end in sight to the misery of hayfever

Twin setbacks for grass pollen allergy projects in development by Asit Biotech and Allergy Therapeutics expose an existential crisis.

After 11 long years Allergy sees a glimmer of hope

July 19, 2017

FDA’s flashing green light boosts novel drug approvals

No slowdown at the FDA, as regulator remains on track to approve at least 43 new drugs this year.

May 02, 2017

Flurry of FDA activity raises hopes for 2017 approval tally

July 27, 2016

Merck calls time on US allergy market

April 11, 2016

Interview – Allergy Therapeutics sniffs out second chance

February 17, 2015

DBV’s moment of truth

April 14, 2014

Cytos bows out as asthma drug bombs

April 02, 2014

And the winner is Stallergenes... for now

March 18, 2014

Circassia emerges as one of the UK’s most valuable life science companies

December 13, 2013

Stallergenes and ALK-Abelló take a step closer to the US market

Load More